J. A. Arjona Ferreira

发表

Predicting steady‐state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus *

M. Takeuchi, M. Narukawa, S. Kanazu, 2009, Diabetes, obesity & metabolism.

Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.

B. Goldstein, G. Golm, K. Kaufman, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

J. Chan, M. Davies, K. Kaufman, 2008, Diabetes, obesity & metabolism.

Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy

N. Tajima, T. Kadowaki, M. Odawara, 2013, Diabetology International.

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Y. Iwamoto, J. Amatruda, K. Nonaka, 2010, Endocrine journal.

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double‐blind trial

N. Tajima, T. Kadowaki, Y. Iwamoto, 2010, Diabetes, obesity & metabolism.

Relugolix Combination Therapy for Uterine Leiomyoma–Associated Pain in the LIBERTY Randomized Trials

A. Al-Hendy, E. Stewart, E. Hunsche, 2022, Obstetrics and gynecology.

Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers

J. A. Arjona Ferreira, T. Yokota, K. Fukumura, 2018, Clinical pharmacology in drug development.

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study

L. Webster, B. Morlion, Tadaaki Yamada, 2018, Pain.

Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

A. Al-Hendy, E. Stewart, R. Venturella, 2021, The New England journal of medicine.

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

R. Echols, H. Krenz, J. A. Arjona Ferreira, 2016, Journal of clinical pharmacology.

Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials

Tadaaki Yamada, J. A. Arjona Ferreira, M. Hale, 2019, Pain.

A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain

L. Webster, Tadaaki Yamada, J. A. Arjona Ferreira, 2017, Pain medicine.

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

M. Marre, N. Barzilai, B. Goldstein, 2013, Diabetes Care.

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function

R. Echols, J. A. Arjona Ferreira, T. Wajima, 2016, Antimicrobial Agents and Chemotherapy.

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

R. Echols, T. Sawada, G. Morgan, 2017, Open forum infectious diseases.

Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance

Y. Terauchi, T. Kadowaki, B. Goldstein, 2015, Diabetes, obesity & metabolism.

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes

N. Tajima, T. Kadowaki, A. Sato, 2013, Journal of diabetes investigation.

Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.

Tadaaki Yamada, J. A. Arjona Ferreira, M. Hale, 2017, The lancet. Gastroenterology & hepatology.

(426) Effect of naldemedine, a peripherally acting μ-opioid receptor antagonist, on QT interval.

J. A. Arjona Ferreira, E. Migoya, K. Fukumura, 2016, The journal of pain : official journal of the American Pain Society.

Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

N. Tajima, T. Kadowaki, M. Odawara, 2011 .

(479) A phase 2a, randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic non-cancer pain and opioid-induced bowel dysfunction.

L. Webster, J. A. Arjona Ferreira, T. Nagata, 2016, Journal of Pain.

A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women

J. A. Arjona Ferreira, E. Migoya, A. Lukes, 2023, Clinical Pharmacokinetics.

Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control

N. Tajima, T. Kadowaki, M. Odawara, 2011 .

L. Webster, Tadaaki Yamada, J. A. Arjona Ferreira, 2017, Pain medicine.

Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis

J. A. Arjona Ferreira, E. Migoya, 2022, F&S reports.

LIBERTY Randomized Withdrawal Study: Relugolix Combination Therapy for Heavy Menstrual Bleeding Associated With Uterine Fibroids.

R. Venturella, R. Wagman, J. A. Arjona Ferreira, 2023, American journal of obstetrics and gynecology.